These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 18585457)

  • 21. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies.
    Pedersen AE; Jungersen MB; Pedersen CD
    Immunology; 2011 Jun; 133(2):239-45. PubMed ID: 21426340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
    Pers YM; Jorgensen C
    Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
    Looney RJ
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
    Tedder TF; Baras A; Xiu Y
    Springer Semin Immunopathol; 2006 Dec; 28(4):351-64. PubMed ID: 17091246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical applications of anti-CD20 antibodies.
    Gopal AK; Press OW
    J Lab Clin Med; 1999 Nov; 134(5):445-50. PubMed ID: 10560936
    [No Abstract]   [Full Text] [Related]  

  • 28. Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies.
    Taylor RP; Lindorfer MA
    Mol Pharmacol; 2014 Nov; 86(5):485-91. PubMed ID: 24944188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights.
    Silverman GJ
    Front Biosci; 2007 Jan; 12():2194-206. PubMed ID: 17127456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [CD20 antibody for treatment of rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():544-8. PubMed ID: 15799415
    [No Abstract]   [Full Text] [Related]  

  • 31. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
    Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
    Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
    Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
    Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
    Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
    Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.
    Castillo J; Milani C; Mendez-Allwood D
    Expert Opin Investig Drugs; 2009 Apr; 18(4):491-500. PubMed ID: 19335277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B cell depletion in autoimmune disease.
    Gorman C; Leandro M; Isenberg D
    Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S17-21. PubMed ID: 15180893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art.
    Witkowska M; Smolewski P
    Curr Drug Targets; 2016; 17(9):1072-82. PubMed ID: 26343115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 40. CD20 as a target for therapeutic type I and II monoclonal antibodies.
    Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
    Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.